Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results

Rhea-AI Summary

Neurocrine Biosciences, Inc. (NBIX) has scheduled its Q4 & Year-End 2023 financial results conference call and webcast for February 7, 2024. The press release and conference call will be held at 4:00 a.m. PT / 7:00 a.m. ET and 5:00 a.m. PT / 8:00 a.m. ET, respectively. The company has provided domestic and international dial-in numbers, along with the conference ID. The webcast will be available on the company's website and a replay will be archived for approximately one month.

Conference Call and Webcast Scheduled for Wednesday, February 7

SAN DIEGO, Jan. 17, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on February 7, 2024.

The schedule for the press release and conference call / webcast is as follows:

		•	Q4 & Year-End 2023 Press Release:	February 7, 2024 at 4:00 a.m. PT / 7:00 a.m. ET
		•	Q4 & Year-End 2023 Conference Call:	February 7, 2024 at 5:00 a.m. PT / 8:00 a.m. ET
		•	Domestic Dial-In Number:	800-225-9448
		•	International Dial-In Number:	203-518-9708
		•	Conference ID:	NBIX

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)

NEUROCRINE is a registered trademark of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2023-financial-results-302037524.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When is Neurocrine Biosciences' Q4 & Year-End 2023 financial results conference call and webcast scheduled?

The conference call and webcast are scheduled for February 7, 2024, at 5:00 a.m. PT / 8:00 a.m. ET.

What are the domestic and international dial-in numbers for the conference call?

The domestic dial-in number is 800-225-9448, and the international dial-in number is 203-518-9708.

Where can the webcast be accessed?

The webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.